TRDA Q3 2022 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$26M

Net Income

-$25M

EPS (Diluted)

$-0.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$274M

Total Liabilities

$41M

Stockholders' Equity

$233M

Cash & Equivalents

$53M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$26M	-$14M	-80.6%
Net Income	-$25M	-$14M	-74.2%